Back to results
US 5,686,449 AGranted
1,5-benzodiazepines useful as gastrinor CCK-antagonists
AssigneeGlaxo Wellcome Inc.
InventorsMaria Elvira Tranquillini, Gabriella Finizia, Antonella Ursini
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof having gastrin and/or CCK-B antagonist activity.
Claims15
A compound of general formula (I) ##STR11## wherein R.sup.1 represents a C.sub.3-7 cycloalkyl, C.sub.7-11 bridgedcycloalkyl or C.sub.1-6 alkyl group which alkyl group may be substituted by a hydroxy, C.sub.1-4 alkoxy, phenyl, C.sub.1-6 alkoxycarbonyl, C.sub.3-7 cycloalkyl, or C.sub.7-11 bridgedcycloalkyl group;
- R.sup.2 represents a substituted or unsubstituted phenyl group (wherein the substituents may be 1 or 2 of halo, C.sub.1-4 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, C.sub.1-4 alkylthio or (CH.sub.2).sub.n R.sup.4 wherein R.sup.4 is hydroxy, C.sub.1-4 alkoxy, CO.sub.2 R.sup.5, NR.sup.5 R.sup.6, SO.sub.2 NR.sup.5 COR.sup.7, CONR.sup.5 SO.sub.2 R.sup.7, or R.sup.4 represents a tetrazole, carboxamidotetrazole or 3-trifluoromethyl-1,2-4-triazole group, which groups may be substituted on one of the nitrogen atoms by a C.sub.1-4 alkyl group;
- R.sup.3 represents C.sub.3-7 cycloalkyl, C.sub.7-11 bridged cycloalkyl or C.sub.1-6 alkyl which alkyl group may be substituted by a phenyl, C.sub.3-7 cycloalkyl or C.sub.7-11 bridged cycloalkyl group;
- R.sup.5 represents hydrogen or a C.sub.1-4 alkyl group;
- R.sup.6 independently represents hydrogen or a C.sub.1-4 alkyl group or the group SO.sub.2 CF.sub.3 ;
- R.sup.7 represents C.sub.1-4 alkyl;
- R.sup.8 represents hydrogen or a halogen atom;
- m is zero, 1 or 2;
- X represents oxygen or NH;
- n is zero or 1;
- and pharmaceutically acceptable salts thereof.
7 more elements
A compound selected from
- N-1-(Adamantylmethyl)-2,4-dioxo-5-(2-hydroxyethyl)-2,3,4,5-tetrahydro-1H-1 ,5-benzodiazepin-3-yl!-N'-phenylurea;
- N-1-(1-Adamantylmethyl)-2,4-dioxo-5-(2-methoxyethyl)-2,3,4,5-tetrahydro-1H -benzodiazepin-3-yl!-N'-phenylurea;
- N-1-(1-Adamantylmethyl)-2,4-dioxo-5-(3-methylbut-1-yl)-2,3,4,5-tetrahydro- 1H-1,5-benzodiazepine-3-yl!-N'-phenylurea;
- N-1-(1-Adamantylmethyl)-2,4-dioxo-5-(cyclohexyl)-2,3,4,5-tetrahydro-1H-1,5 -benzodiazepine-3-yl!-N'-phenylurea;
- N-1-Adamantylmethyl)-2,4-dioxo-5-(3-methylbut-1-yl)-2,3,4,5-tetrahydro-1H- 1,5-benzodiazepine-3-yl!-N'-3-(N,N-dimethylamino)phenylurea;
- N-1-Adamantylmethyl)-3-3(N,N-dimethylamino)phenyloxycarbonyl!amino-2,4-di oxo-5-(3-methylbut-1-yl)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine;
- N-1-(Adamantylmethyl)-2,4-dioxo-5-(3-hydroxypropyl)-2,3,4,5-tetrahydro-1H- 1,5-benzodiazepin-3-yl!-N'-phenylurea;
- N-1-(Adamantylmethyl)-2,4-dioxo-5-(2-ethoxycarbonylethyl)-2,3,4,5-tetrahyd ro-1H-1,5-benzodiazepin-3-yl!-N'-phenylurea, and enantiomers thereof.
5 more elements
A compound selected from
- 1-(1-Adamantan-1-yl-5-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzob!1,4!d iazepine-3-yl)-3-m-tolyl-urea;
- 1-(1-Adamantan-1-yl-5-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzob!1,4!d iazepine-3-yl)-3(4-fluoro-phenyl)-urea;
- 3-3-(1-Adamantan-1-yl-5-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzob!1, 4!diazepine-3-yl)-ureido!benzoic acid;
- and more especially enantiomers thereof.
1 more element
A process for the preparation of a compound of formula (I) which comprises
- (a) reacting an amine of formula (II) wherein R.sup.1,R.sup.3,R.sup.8 and m are as defined in formula (I) ##STR12## with an isocyanate R.sup.2 NCO and compound of R.sup.2 XCOCl wherein R.sup.2 and X have the meanings defined in formula (I);
- (b) reacting a compound corresponding to formula (I) but wherein R.sup.1 or R.sup.3 represents a hydrogen atom with an alkylating agent R.sup.1 Y or R.sup.3 Y wherein Y is a leaving group and R.sup.1 or R.sup.3 is an optionally substituted alkyl group as defined in formula (I) and thereafter if necessary or desired either before or alter any separation into its stereochemical isomers the conversion of one compound of the invention into another compound of the invention.
A compound of the formula (I) ##STR13## wherein R.sup.1 represents a C.sub.3-7 cycloalkyl, C.sub.7-11 bridgedcycloalkyl or C.sub.1-6 alkyl group which alkyl group may be substituted by a hydroxy, phenyl, C.sub.1-6 alkoxycarbonyl, C.sub.3-7 cycloalkyl, or C.sub.7-11 bridgedcycloalkyl group;
- R.sup.2 represents a substituted or unsubstituted phenyl group (wherein the substituents may be 1 or 2 of halo, C.sub.1-4 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, C.sub.1-4 alkylthio or (CH.sub.2).sub.n R.sup.4 wherein R.sup.4 is hydroxy, C.sub.1-4 alkoxy, CO.sub.2 R.sup.5, NR.sup.5 R.sup.6, SO.sub.2 NR.sup.5 COR.sup.7, CONR.sup.5 SO.sub.2 R.sup.7, or R.sup.4 represents a tetrazole, carboxamidotetrazole or 3-trifluoromethyl-1,2-4-triazole group, which groups may be substituted on one of the nitrogen atoms by a C.sub.1-4 alkyl group;
- R.sup.3 represents C.sub.3-7 cycloalkyl, C.sub.7-11 bridged cycloalkyl or C.sub.1-6 alkyl which alkyl group may be substituted by a phenyl, C.sub.3-7 cycloalkyl or C.sub.7-11 bridged cycloalkyl group;
- R.sup.5 represents hydrogen or a C.sub.1-4 alkyl group;
- R.sup.6 independently represents hydrogen or a C.sub.1-4 alkyl group or the group SO.sub.2 CF.sub.3 ;
- R.sup.7 represents C.sub.1-4 alkyl;
- R.sup.8 represents hydrogen or a halogen atom;
- m is zero, 1 or 2;
- X represents oxygen or NH;
- n is zero or 1;
- and pharmaceutically acceptable salts thereof.
7 more elements
Dependencies are inferred from the claim text.